T R U E G F R V E R S U S E S T I M A T E D G F R
Because of the circadian rhythm in kidney function the true glomerular filtration rate (GFR) is historically considered to be the average GFR measured by urinary inulin clearance over a 24-h period [1] . In clinical practice, it is impossible to measure GFR during such a prolonged period. Therefore, three methods have been developed to estimate GFR. First, GFR can be assessed by measuring during a shorter period of time the clearance of an exogenous filtration marker such as iohexol, iothalamate, 51 Cr-EDTA or DTPA. This is generally regarded to be the gold standard for measuring kidney function, and therefore is often referred to as measured GFR (mGFR). However, it should be kept in mind that this is a misunderstanding and that measuring the clearance of these filtration markers is actually also just an estimation of true GFR. Second, the GFR can be estimated by measuring the 24-h urinary clearance of an endogenous marker, such as creatinine or urea. It is well known that creatinine clearance overestimates true GFR due to tubular creatinine secretion, whereas urea clearance underestimates GFR due to tubular urea reabsorption. For these reasons taking the average of urea and creatinine clearance could provide an acceptable estimation of the true GFR, as the bias induced by creatinine excretion and urea reabsorption are expected to cancel each other out [2] . Although this is an attractive option to estimate true GFR, it is not often used. Third, GFR can be estimated using an equation that incorporates serum creatinine, age, gender and race, such as the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [3] . In clinical practice this is the reference method.
Since these three aforementioned methods all yield an estimation of GFR, which method has the best correlation with true GFR is the question. This issue could be investigated in a crosssectional study that compares true GFR measured as inulin clearance over a 24-h period with GFR estimated with each of these three methods. Given that kidney function is causally associated with incidence of end-stage renal disease (ESRD) and mortality, another option is to investigate which of the three GFR estimates has the strongest association with incidence of these hard end points. In this issue of NDT, Methven et al. published the results of an observational study that addressed this question using data from the Swedish CKD registry [4] .
W H A T A R E T H E F I N D I N G S O F T H I S S T U D Y ?
The Swedish CKD registry is a unique database, because many CKD patients in Sweden undergo routine measurement of GFR using iohexol as an exogenous filtration marker. In a cohort of 2705 CKD patients, iohexol mGFR, average urinary ureacreatinine clearance and estimated GFR (eGFR) were compared with regard to their association with all-cause mortality. This manuscript addresses the question of whether clinicians should measure mGFR instead of eGFR to assess mortality risk.
Methven et al. found that mGFR had a stronger association with mortality and better performance to predict mortality than eGFR, whereas creatinine clearance did not outperform eGFR in these aspects. In adjusted Cox regression models, each 1 mL/ min/1.73 m 2 lower mGFR, urinary urea-creatinine clearance or eGFR resulted in an increase in mortality risk of 5.3% for mGFR, 2.3% for creatinine clearance and 1.7% for eGFR. In prognostic models, replacing eGFR with mGFR resulted in an integrated discrimination improvement (IDI) of 0.023. The IDI is a statistical metric that can be used to calculate whether a biomarker improves the prediction of an end point [5] . The further this value is from zero, the better the biomarker performs at identifying patients at risk for the outcome event of interest. The IDI of 0.023 that was found in the study by Methven is considered to be only a modest improvement, leading the authors to conclude that eGFR may be sufficient in clinical practice to predict mortality risk. Of note, urinary urea-creatinine clearance did not improve the IDI for mortality compared with eGFR. 
eGFR is commonly deemed inferior to mGFR, because the equations to estimate GFR were created to obtain values that correspond to mGFR. During the last decade a flurry of crosssectional studies has been performed, comparing eGFR with mGFR in various study populations with varying results. In these reports, the accuracy of eGFR is compared with mGFR as the reference using Bland-Altman plots. These plots report bias (i.e. systematic error) and dispersion, from which precision is calculated (i.e. variability). By doing so, mGFR is adopted as the gold standard, suggesting that mGFR measurement is not biased and has excellent precision. However, we should realize that mGFR also has several limitations that make it a goldplated rather than a gold standard.
First of all, there is no standardization of the assays used to measure serum and urine levels of the exogenous GFR markers. A recent study compared iohexol mGFR with iothalamate mGFR [6] . Both markers were assessed contemporaneously in the same patients and in the same blood samples. Interestingly, iohexol was measured by two different assays, liquid chromatography-tandem mass spectrometry (LC-MS/MS) and high-performance liquid chromatography (HPLC). Figure 1 shows the Bland-Altman plots that were provided. These plots indicate that the two analytical methods result in substantial differences in mean mGFR, and also that the two methods have limited agreement. In comparison with iothalamate, mGFR based on iohexol measured by LC-MS/MS resulted in a bias of À10.6% [95% confidence interval (95% CI) À28.2 to 6.9%], whereas the bias for mGFR based on iohexol measured with HPLC was only 1.7% (95% CI À26.5 to 23.0%). Consequently, in a patient with an iothalamate mGFR of 50 mL/min/1.73 m 2 , using iohexol measured by LC-MS/MS could result in an mGFR ranging between 36 and 53 mL/min/1.73 m 2 , and for iohexol measured by HPLC in an mGFR ranging between 37 and 62 mL/min/1.73 m 2 . Another study that compared the urinary clearance of iohexol measured by LC-MS/MS and iothalamate found similar results with regard to bias and dispersion [7] . Figure 2 depicts the results of the direct comparison of mGFR based on iohexol measured by LC-MS/MS or HPLC. This graph shows that using HLPC as the analytical method to measure iohexol yielded an mGFR that was 8.9% higher than when LC-MS/MS was used. Not only is there a systematic bias, the dispersion in Figure 2 indicates that there is also substantial imprecision in mGFR when LC-MS/MS or HPLC is used to measure iohexol. Due to a lack of standardization, it is not clear which iohexol assay is responsible for this imprecision. In contrast, the assay for creatinine was standardized in 2006, to ensure accurate estimation of GFR. Nowadays, clinical chemistry laboratories around the world are advised to use an enzymatic assay to measure creatinine, and to calibrate results to an international standard [8] [9] [10] .
Second, there is a lack of protocol standardization to estimate GFR based on exogenous filtration markers. To obtain an mGFR (almost) equal to true GFR, one should ideally perform a continuous infusion of the exogenous marker and collect multiple blood samples and collect urine over 24 h. Such a procedure would be impossible to incorporate into clinical care, and would even be difficult in clinical studies. In practice, patients, therefore, receive a single injection of a labelled exogenous marker and then blood samples are obtained in the hours after the injection to estimate GFR from the plasma disappearance curve. With this method, the GFR is estimated with an equation that incorporates time after injection, the dose of the injected marker, concentration at the time of measurement and an estimation of the volume of distribution. This form of GFR measurement introduces several sources of bias and variability. For instance, several equations are available to calculate GFR from the plasma disappearance curves that render different results [11] [12] [13] . In addition, results will theoretically be dependent on how often and when plasma samples are obtained. It has indeed been shown that the intra-patient coefficient of variation of repeated mGFR measurements decreases when more blood samples are taken [14] . Others showed that the GFR can be systematically overestimated when samples are drawn too early. Agarwal et al. investigated the effect of study duration on subsequently obtained mGFR values. These authors found that the mGFR value after 2 h is 54% higher and after 5 h 17% higher when compared with the mGFR value that is obtained after 10 h of blood sampling [14] . This overestimation was higher when GFR was lower. Furthermore, bolus injection of an exogenous marker leads to serum concentrations of the marker under study that follow a two-compartment pharmacokinetic model [rapid initial decline of plasma levels of the marker reflecting tissue distribution, followed by slower decline during several hours indicating (renal) clearance] [14] . Importantly, many studies use a mono-compartment, log-linear decline model to estimate GFR, which does not take into account the initial distribution phase, and may thus be expected to yield biased GFR results. This bias is expected to be present especially in patients with non-standard body composition, such as patients with oedema or after limb amputation [14] . To improve GFR estimation from exogenous filtration markers, both the protocol (when and how often to collect blood and urine samples) as well as the equation that is used to estimate mGFR from a plasma disappearance curve needs to be optimized and subsequently internationally standardized.
Third, creatinine has been criticized as glomerular filtration marker to be used in estimation equations, because serum concentration of creatinine is dependent not only of GFR, but also of non-GFR determinants. As is generally appreciated, serum creatinine concentration is influenced by tubular creatinine secretion and by muscle mass. Thus, creatinine-based eGFR is less reliable in patients with a high or low muscle mass for a given age and gender [15] . However, creatinine is not the only GFR marker with non-GFR determinants. The ideal marker for measuring GFR is water soluble, inert, freely filtered, not reabsorbed or secreted by the tubule, and has no extra-renal clearance [16] . Most endogenous markers also do not meet these criteria. For example, iothalamate is subject to tubular secretion [17, 18] , iohexol and EDTA are subject to tubular reabsorption [19, 20] , iohexol and DTPA suffer from protein binding [7, 21] , and iothalamate and DTPA are subject to extra-renal clearance that can vary between individuals [21, 22] .
Given the abovementioned factors, it is not surprising that the various exogenous markers for the measurement of GFR do not perform equally. A systematic review that compared renal and plasma clearance of exogenous filtration markers with renal inulin clearance found that plasma clearance of iohexol and Cr-EDTA had the least bias [23] . The P30, the percentage of GFR estimates that lies within 30% of mGFR, is a metric that is often used to express the accuracy of a certain GFR estimation method. For plasma clearance of iohexol and iothalamate, P30 compared to inulin-based GFR was 84% (95% CI 78-90) and 61% (95% CI 47-80), respectively. In comparison, two other studies showed that the creatinine-based CKD-EPI GFR estimation equation yielded a P30 that was similar (78%, 95% CI 72-84, compared to inulin mGFR) or even slightly better (87%, 95% CI 85-89, compared to iothalamate mGFR) [24, 25] . Combined, these results indicate that GFR measured with exogenous markers does not consistently outperform creatininebased equations to estimate GFR.
e G F R A N D m G F R V E R S U S H A R D E N D P O I N T S
Besides the present study by Methven et al., five other studies have compared eGFR with mGFR with regard to their association with incidence of ESRD and mortality [26] [27] [28] [29] [30] . Their results are summarized in Table 1 . This table shows divergent results. Some studies found eGFR and others mGFR to have stronger associations with ESRD and mortality, whereas others did not find differences. These varying results cannot be explained by the exogenous filtration marker that was used to estimate GFR, because in four out of five studies this was urinary iothalamate clearance. It seems that other factors are important, for example, the protocol that was used for sample collection and/or the assay for iothalamate. Overall, these data indicate that mGFR does not consistently outperform eGFR with regard to the association with incidence of ESRD and mortality, and that the improvement of risk prediction when using mGFR instead of eGFR is modest at best.
R E P E A T E D M E A S U R E S O F e G F R A N D m G F R
The studies in Table 1 investigated the associations of a single measurement of eGFR and mGFR with incidence of hard end points. However, in clinical practice repeated measures of eGFR are used to determine kidney disease progression and prognosis. A meta-analysis has shown that change in eGFR during a 2-year period is associated with subsequent development of ESRD and mortality [31] . Only one study compared change in eGFR versus change in mGFR with respect to their association with incident ESRD and mortality [30] . Interestingly, these investigators found that eGFR slopes had a stronger association with incident ESRD as well as with mortality than mGFR slopes. These data suggest that it may be better to use eGFR rather than mGFR for monitoring change in kidney function over time.
C O N C L U S I O N
Creatinine-based equations to estimate GFR are often criticized because of their alleged imprecision. The study by Methven et al. in this issue of NDT showed that GFR estimated by iohexol clearance yields only a modest improvement in the prediction of mortality compared with GFR estimated by the CKD-EPI equation in a large population of CKD patients. This result adds to other research which has shown that GFR measured with exogenous filtration markers does not consistently outperform eGFR with respect to precision of GFR measurement, nor with respect to the strength of the associations with incident ESRD and mortality. In our opinion, much of the criticism expressed toward eGFR is actually a result of the fact that in these studies not a gold standard, but merely a gold-plated standard is used as reference method. A lack of standardization of the assays that are used to measure the exogenous filtration markers, a lack of standardization of protocols for how and when blood and urine samples should be collected, which equation to use to estimate GFR from the plasma disappearance curve, as well as non-GFR determinants of the exogenous filtration markers that are applied, all lead to the conclusion that GFR measured by these exogenous markers results in rather variable results. When studies compare the performance of creatinine-based GFR estimating equations with GFR measured by exogenous filtration markers, the bias and imprecision that is found is in general attributed solely to the limitations of the creatinine-based GFR estimating equations. Studies that compared the performance of two exogenous filtration markers indicate, however, that much of the bias and imprecision is actually due to the limitations of the exogenous filtration marker that is used as the reference method. These considerations indicate that creatininebased equations to estimate GFR will perform considerably better than many clinicians and epidemiologists assume.
Moreover, it is important to realize that creatinine is measured by a standardized assay that is calibrated versus an international standard. This, in combination with the universal application of the same creatinine-based equation to estimate GFR, indicates that consistent, fairly reliable results across the world can be obtained, for a fraction of the costs of measurement of GFR by exogenous filtration markers. That does not seem too bad after all.
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